Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study is to evaluate the safety and efficacy of RVL-1201 Ophthalmic
Solution in the treatment of acquired blepharoptosis (ptosis) and to assess the safety and
comfort of RVL-1201 Ophthalmic Solution for an extended dosing period of 6 weeks.